Pure Global AI
NCT05292196Recruiting

A Phase II Clinical Trial of TQC3721 Suspension for Inhalation

A Randomized, Double-blind, Placebo-parallel, Multicenter Phase II Trial of the Efficacy and Safety of TQC3721 Suspension for Inhalation in the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Chronic Obstructive Pulmonary Disease (COPD)
Drug/Device/Intervention
TQC3721 suspension for inhalation
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Location
Chongqing,Lanzhou,Zhanjiang,Ha'erbin,Xuzhou,Yangzhou,Nanchang,Changchun,Shenyang,Chengdu,Mianyang, China
Timeline & enrollment
Phase
Phase 2
Start date
May 20, 2022
End date
May 01, 2024
Enrollment
460 participants
Primary outcome

The peak of Forced Expiratory Volume(FEV1)

Summary

TQC3721 suspension for inhalation is a PDE3/4 inhibitor developed by Chia Tai Tianqing
 Pharmaceutical Group Co., LTD., which can simultaneously achieve bronchial smooth muscle
 relaxation and anti-inflammatory effects. This is a randomized, double-blind,
 placebo-parallel, phase II trial of the efficacy and safety of inhaled TQC3721
 suspension/placebo at different doses in patients with moderate to severe chronic obstructive
 pulmonary disease. Objective To evaluate the efficacy, safety and tolerability of TQC3721
 inhalation suspension in the treatment of moderate to severe Chronic Obstructive Pulmonary
 Disease (COPD).

ICD-10 classifications
Other chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease, unspecifiedOther specified chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease with acute exacerbation, unspecifiedChronic obstructive pulmonary disease with acute lower respiratory infection
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05292196
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05292196 through Pure Global AI's free database. This Phase 2 trial is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and is currently Recruiting. The study focuses on Chronic Obstructive Pulmonary Disease (COPD). Target enrollment is 460 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.